Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
GM-CSF is considered to have a key role in the initiation and progression of arthritic
inflammation. The purpose of this study is to evaluate the safety, preliminary efficacy,
pharmacokinetics, and immunogenicity of multiple doses of MOR103, a human antibody to GM-CSF,
in patients with active rheumatoid arthritis.